Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Companion diagnostic tests
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
See all tags

Two new diagnostic codes were added to private reimbursement schedule in England in July/August 2018

The Clinical Coding and Schedule Development (CCSD) develops and maintains procedural and diagnostics nomenclature for private payers in England. Once codes are added to the Schedule, a rivate insurance company can develop reimbursement tariff for these procedures and tests.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in July/August with a recommended adoption date of 1st November 2018:

  • 18S rRNA gene and Sequencing (3545G)
  • ELA2 Cyclic Neutropenia Genetic Screen (3546G)

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

Tags
UK
Private health insurance
Reimbursement
In-vitro diagnostic tests

The latest related news

30
May 2025

Common Package of Benefits updated in Spain

On May 13, 2025, the Common Package of Benefits of the Spanish National Health System (NHS) was amended. The med tech-related updates mostly concerned in-vitro diagnostics, gastrointestinal, e-Health, cardiovascular, ENT, ophthalmology, oral health, and neurology fields.
Read more
15
May 2025

2025/26 National Genomic Test Directory released in England

On May 6, 2025, NHS England issued an updated version of the National Genomic Test Directory for 2025/26, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. One new code (test-indication combination) was introduced in the Test Directory for cancer, and one for rare and inherited diseases.
Read more
13
May 2025

New outpatient tariff system approved in Switzerland

On April 30, 2025, the Federal Council approved the new outpatient reimbursement system, comprising the TARDOC catalog of individual service tariffs (ambulatory settings) and the flat-rate system (day case settings). The approval is valid until December 31, 2028, allowing for potential adjustments post-implementation. The TARDOC and outpatient flat rates will take effect on January 1, 2026.
Read more
12
May 2025

Med Tech-related health technology assessments in Wales in March-April 2025

In March-April 2025, Health Technology Wales (HTW) accomplished one full appraisal of permanent implant brachytherapy devices for unresectable pancreatic cancer. Five Med Tech-related Topic Exploration Reports were published (on superior rectal artery embolization, glucose monitoring systems in neonates, gender-affirming surgery, telemetric intracranial pressure monitoring, tumor-profiling tests to guide bisphosphonate treatment in cancer).
Read more